Trimodal Therapy Approaches for Localized Rectal Cancer

Restricted access

Excellent long-term outcomes and manageable toxicity are being achieved with contemporary treatment strategies for rectal cancer. Short-course radiotherapy is now an acceptable standard. Total neoadjuvant therapy (TNT), which incorporates induction or consolidation chemotherapy, has improved the delivery of treatment regiments. TNT is now a standard of care, although the sequencing of radiation and chemotherapy in TNT, appropriate amount of chemotherapy in TNT, and addition of irinotecan to the regimen are still being debated. Nonoperative management of rectal cancer appears to be a safe option for select patients, but it is not yet an NCCN recommendation. In addition, the omission of radiation is being evaluated as a treatment option in some cases.

Disclosures: Dr. Willett has disclosed that he has no relevant financial relationships.

Correspondence: Christopher G. Willett, MD, Department of Radiation Oncology, Duke Cancer Institute, 30 Duke Medicine Circle, Room 05143 Morris, Box 3085, Durham, NC 27710. Email: christopher.willett@duke.edu
  • 1.

    Erlandsson J, Holm T, Pettersson D, Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol 2017;18:336346.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Bujko K, Mowacki M, Nasierowska-Guttmejer A, Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004;72:1524.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Ngan SY, Burmeister B, Fisher RJ, Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012;30:38273833.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Bujko K, Wyrwicz L, Rutkowski A, Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol 2016;27:834842.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Ciseł B, Pietrzak L, Michalski W, Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol 2019;30:12981303.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Gao P, Huang XZ, Song YX, Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study. BMC Cancer 2018;18:234.

  • 7.

    Xu Z, Mohile SG, Tejani MA, Poor compliance with adjuvant chemotherapy use associated with poorer survival in patients with rectal cancer: an NCDB analysis. Cancer 2017;123:5261.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Khrizman P, Niland JC, ter Veer A, Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a National Comprehensive Cancer Network analysis. J Clin Oncol 2013;31:3038.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Bosset JF, Calais G, Mineur L, Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 2014;15:184190.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Marco MR, Zhou L, Patil S, Consolidation mFOLFOX6 chemotherapy after chemoradiotherapy improves survival in patients with locally advanced rectal cancer: final results of a multicenter phase II trial. Dis Colon Rectum 2018;61:11461155.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Fokas E, Allgäuer M, Polat B, Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol 2019;37:32123222.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Hospers G, Bahadoer RR, Dijkstra EA, Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: the randomized RAPIDO trial [abstract]. Presented at the ASCO 2020 Annual Meeting ; May 29–31, 2020; Chicago, Illinois. Abstract 4006.

    • Search Google Scholar
    • Export Citation
  • 13.

    Conroy T, Lamfichekh N, Etienne PL, Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: final results of the PRODIGE 23 phase III trial, a UNICANCER GI trial [abstract]. Presented at the ASCO 2020 Annual Meeting ; May 29–31, 2020; Chicago, Illinois. Abstract 4007.

    • Search Google Scholar
    • Export Citation
  • 14.

    Benson AB III, Venook AP, Al-Hawary MM, NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. Version 2.2020. Accessed March 3, 2020. Available at NCCN.org

    • Search Google Scholar
    • Export Citation
  • 15.

    Habr-Gama A, Gama-Rodrigues J, São Julião GP, Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys 2014;88:822828.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Martens MH, Maas M, Heijnen LA, Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer. J Natl Cancer Inst 2016;108:djw171.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Appelt AL, Pløen J, Harling H, High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol 2015;16:919927.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Smith JJ, Strombom P, Chow OS, Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol 2019;5:e185896.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Smith JJ, Chow OS, Gollub MJ, Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer 2015;15:767.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Garcia-Aguilar J, Patil S, Kim J, Preliminary results of the OPRA trial [abstract]. Presented at the ASCO 2020 Annual Meeting; May 29–31, 2020; Chicago, Illinois. Abstract 4008.

    • Crossref
    • Export Citation
  • 21.

    Gynne-Jones R, Wyrwicz L, Tiret E, Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol 2017;28(Suppl 4):iv2240.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22.

    Rullier E, Vendrely V, Asselineau J, Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial. Lancet Gastroenterol Hepatol 2020;5:465474.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Yao Y, Xu X, Yang L, Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer. Cell Stem Cell 2020;26:1726.

  • 24.

    Schrag D, Weiser MR, Goodman KA, Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol 2014;32:513518.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 69 69 69
PDF Downloads 19 19 19
EPUB Downloads 0 0 0